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Indomethacin and staurosporine reverse a2 inhibition of water
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Indomethacin and staurosporine reverse a2 inhibition of water trans-
port in rat IMCD. These studies were conducted to determine if the
prostaglandin-synthesis inhibitor indomethacin or the protein kinase C
(PKC) inhibitor staurosporine affect the inhibition of osmotic water
permeability (Pf) by the alpha-2 (112) agonist dexmedetomidine in the rat
inner medullary collecting duct (TMCD). Terminal IMCDs from Wistar
rats were perfused and P1 was increased with either 220 M argifline
vasopressin (AVP) or 0.1 msi 8-chlorophenylthio cyclic adenosine mono-
phosphate (8CPTcAMP). All agents were added to the bathing solution.
Dexmedetomidine at 100 flM inhibited both AVP- and 8CPTcAMP-
stimulated P1. When P1 was increased by AVP, indomethacin at 0.1 m or
5 jLM reversed the dexmedetomidine-induced inhibition by 68% and 43%,
respectively. When Pf was increased by 8CPTcAMP, indomethacin at 0.1
m or 5 jiM reversed inhibition by 83% and 70%, respectively. Indometh-
acm increased AVP and 8CPTcAMP-stimulated Pf by 20 to 30% and
dexmedetomidine inhibited the AVP+ indomethacin-stimulated P1. Stau-
rosporine at 10 flM yielded similar results. Results suggest that PKC and
prostaglandins are involved in the 112 mediated mechanism, and stauro-
sporine and indomethacin-sensitive cellular mediators modulate basal Pf.
Alpha-2 (a2) agonists inhibit arginine vasopressin (AVP)-
stimulated increase of osmotic water permeability (Pf) in mam-
malian collecting duct nephron segments [1—4]. The classic expla-
nation for this mechanism is that a2-adrenoceptors couple to an
inhibitory G (G1) protein that reduces adenylyl cyclase activity.
This is reasonable given that 3'-5' cyclic adenosine monophos-
phate (cAMP) is the second messenger mediating AVP-induced
increase in water permeability and 112 agonists reduce AVP-
stimulated increase in cAMP accumulation [5—8].
However, studies from perfusion experiments of isolated tu-
bules demonstrated that 112 agonists reduced transport stimulated
by nonhydrolyzable analogs of cAMP. Under these conditions
where cellular cAMP levels remain constant, 02 agonists inhibited
lumen-to-bath sodium transport (Jb), and Pf in the rat cortical
collecting duct (CCD) [2], and Pf and urea permeability (Pa) in
the rat inner medullary collecting duct (IMCD) [1. These studies
indicate that second messengers other than cAMP are involved in
the a2-mediated mechanism.
Among the key intracellular mediators studied in isolated
collecting duct segments are prostaglandins, protein kinase C
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(P1(C), and calcium. In the rat IMCD, prostaglandin E2 (PGE2)
inhibits Pf via a post-cAMP dependent mechanism that appears to
be linked to PKC activation [9]. In the rabbit CCD, staurosporine
attenuated the PGE2-induced reduction in Pf [101, and indometh-
acm, a cyclooxygenase inhibitor, prevented the known cAMP-
induced reduction in lb [11].
Using the selective 112 agonist dexmedetomidine, we investi-
gated the effects of indomethacin and staurosporine on
mediated inhibition of P1 in the rat IMCD. Both agents reversed
dexmedetomidine-induced inhibition of Pf. These results suggest
that dexrnedetomidine activates prostaglandins and PKC to in-
hibit Pf. Interestingly though, dexmedetomidine reduced Pf when
it was applied after the addition of indomethacin or staurosporine.
This indicates that a very complicated mechanism exists in the
IMCD where 02 adrenoceptors play a major role in regulating
water permeability.
METHODS
Microperfusion of the inner medullary collecting duct
Isolated IMCD segments were isolated and perfused by tech-
niques previously described [12, 13]. Wistar rats were killed by
decapitation, the kidneys were rapidly removed, and small slices
were placed in a chilled dissection solution of the same composi-
tion as the bath described below. IMCD segments were dissected
and isolated from the terminal two-thirds of the inner medulla
[14, 15].
After isolation, the IMCD was transferred to a perfusion
chamber on the stage of an inverted microscope and mounted on
concentric pipettes that suspended the tubule in the bathing
solution. One end of the tubule was drawn by suction into the tip
of one of the outer pipettes. The tip of the inner pipette
containing the luminal perfusion solution or perfusate was ad-
vanced into the lumen of the tubule and perfusion was initiated
via hydrostatic pressure.
The opposite end of the tubule was held in the tip of another
glass micropipette where the perfusate accumulated. The tip of
this pipette was coated with a viscous silicone liquid (Sylgard 184,
Dow Corning) in order to completely separate the perfusate from
the bath. Collected-fluid samples were taken periodically during
an experiment with a constant-volume or volumetric pipette. The
composition of the bath was as follows (in mM): 115 NaCI, 25
NaHCO3, 10 sodium acetate, 5 KCI, 1.0 CaCI2, 1.2 MgSO4, 1.2
NaH2PO4, and 5.5 glucose. All experiments were conducted at
37°C.
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Measurement of osmotic water permeability
Osmotic water permeability (Pf) was determined by measuring
net fluid flux (J) in the presence of a lumen-to-bath osmotic
gradient (80 to 90 to 295 to 300 mOsmlkg H20). The perfusate
was made hypotonic to the bath by reducing the NaC1 concentra-
tion to 50 mtvi. 14C-inulin was added to the perfusate as the
volume marker, and rapid luminal perfusion rates of 20 to 30
nI/mm were used to avoid osmotic equilibration. Perfusion rate
(V1) was calculated as V, = V0(1n0/1n1), where In and In0 are the
inulin activities (in cpm/nl) in the perfusate and collected fluid,
respectively. The collection rate, V0, was determined directly by
measuring the time required to fill the volumetric pipette. J, was
calculated as J,. = (V — V0)/L, where L is the tubule length
measured with an eyepiece micrometer. Each experiment con-
tained four or five experimental periods where three timed fluid
samples were collected in each period. Pf was calculated for each
sample via standard methods and equations [16], and the Pf
reported for an experimental period was the average of the three
individual collections.
Experimental protocols
The sequence of experimental periods in a given protocol is
shown on the abscissa of the figures in the Results section.
Experiments were designed to determine if indomethacin or
staurosporine would affect dexmedetomidine-induced inhibition
of Pf stimulated by either AVP or 8-(4-chlorophenylthio)-cAMP
(8CPTcAMP). In some experiments, the £52 antagonist atipam-
ezole was used to reverse the agonist's effect. Dexmedetomidine
and atipamezole have been reported to be very selective as an 2
agonist and antagonist, respectively [17].
Once the IMCD was mounted on concentric pipettes, perfusion
was initiated and the bathing solution temperature was raised to
37°C over a time period of 10 to 15 minutes. After an equilibration
period of 30 to 35 minutes, the sampling procedure for the control
period began. After three collections were taken in this period, an
experimental agent was added to the bath and after a 15- to
20-minute equilibration period the sampling procedure was re-
peated. Other agents were then added in subsequent periods with
the appropriate equilibration time followed by the sampling
procedure. AVP was used at 220 pvt, 8CPTcAMP at 0.1 mM,
dexmedetomidine and atipamezole at 100 flM, indomethacin at
either 0.1 mM or 5 LM, and staurosporine at 10 nM.
Chemicals
Arginine vasopressin, 8CPTcAMP, indomethacin, and stauro-
sporine were purchased from Sigma Chemical (St. Louis, MO,
USA). Dexmedetomidine and atipamezole were kindly provided
by Dr. Riku Aantaa (Chief of Research, Orion-Farmos Pharma-
ceutical, Turku, Finland). 14C inulin was obtained from New
England Nuclear (Boston, MA, USA).
Statistics
Data were analyzed with a single-factor ANOVA with repeated
measures using the SuperAnovaTM statistical package.
RESULTS
Effect of indomethacin on dexmedetomidine-induced inhibition
of AVP-stimulated P
Experiments began with the control period followed by adding
AVP to the bath which increased Pf (Figs. 1 and 2). The
subsequent addition of dexmedetomidine reduced Pf by 90 to
100%. Indomethacin added at 0.1 m (Fig. IA) or 5 jIM (Fig. 1B)
significantly reversed dexmedetomidine-induced inhibition by
68% and 43%, respectively. Removal of indomethacin in the final
period returned P back to the value observed before indometh-
acm was added.
Figure 2 also shows that indomethacin added to the bath at 0.1
m reversed the dexmedetomidine-induced inhibition of AVP-
stimulated Pf by 90%. In this protocol, the 2 antagonist atipam-
ezole at 100 n added in the final period did not change P5.
A
1±1 245±9 4±3 166±13 7±2
Control AVP AVP AVP +
+ Dex Dex + I
B
AVP
+ Dex
4±1 183±8 22±2 79±5 27±2
300
250
200
5.)
150
u: 1000
50
0
—50
250
200
51)
150
:1
100
50
0
Fig. 1. Indomethacin reverses dexmedetomidine-induced inhibition of
AVP-stimulated Pf. Each line represents a single experiment. Mean SE
is shown above each experimental period. Each period was significantly
different from the previous period (P < 0.001). Abbreviations are: AVP,
arginine vasopressin (220 pM); Dex, dexmedetomidine (100 nM); I,
indomethacin [0.1 mvi (A), 5 sM (B)].
Control AVP AVP AVP + AVP +
+ Dex Dex + I Dex
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Control AVP AVP+ AVP+ AVP+I+
Dex Dex + I Dex + Ati
Fig. 2. Indomethacin reverses dexmedetomidine-induced inhibition of
AVP-stimulated Pn Each line represents a single experiment. Mean SE
is shown above cach experimental period. Each period was significantly
different from the previous period (P < 0.001) except the final period was
not different from the previous one (that is, Ati did not affect Pf).
Abbreviations are: AVP, arginine vasopressin (220 pM); Dex, dexmedeto-
midine (100 nM); I, indomethacin (0.1 mM); Ati, atipamezole (100 nM).
Effect of indomethacin on dexmedetomidine-induced inhibition
of 8CPTcAMP-stimulated P1
This protocol was the same as that in Figure 1 except in lieu of
AVP, 0.1 mrvt 8CPTcAMP was used to stimulate P (Fig. 3). The
addition of indomethacin at 0.1 mM (Fig. 3A) or 5 /LM (Fig. 3B)
significantly reversed the dexmedetomidine-induced inhibition by
83% and 69%, respectively. Removing indomethacin lowered Pf
back to the inhibited level.
Effect of staurosporine on dexmedetomidine-induced inhibition
of AYP- and cAMP-stimulated P1
Dexmedetomidine inhibited AVP-stimulated Pf and the subse-
quent addition of 10 nM staurosporine significantly reversed the
inhibition by 24% (Fig. 4A). Upon the removal of staurosporine,
Pf returned back to the inhibited level. In Figure 4B, the same
protocol was followed using 8CPTcAMP in lieu of AVP. Dexme-
detomidine inhibited 8CPTcAMP-stimulated Pf. The subsequent
addition of 10 nM staurosporine resulted in a slight increase in Pf,
although this increase was not statistically significant. However,
the removal of staurosporine in the final period significantly
reduced Pf.
Effect of dexmedetomidine added after the addition of
indomethacin
After AVP increased Pf from control values, indomethacin
added at either 0.1 m (Fig. 5A) or 5 /.tM (Fig. SB) significantly
increased the AVP-stimulated Pf. Subsequent addition of dexme-
detomidine at 100 nM reduced P in both sets of experiments. The
addition of 100 nM atipamczole (Fig. 5A) or the removal of
dexmedetomidine (Fig. SB) reversed the dexmedetomidine-in-
duced inhibition.
Figure 6 shows the results of the same protocol as Figure SB
except that 0.1 mivi 8CPTcAMP was used in lieu of AVP. The
same profile occurred in that 8CPTcAMP increased P0 indometh-
acm at 5 /.tM produced a slight hut significant increase, dexme-
Control cAMP cAMP + cAMP + cAMP
Dex Dex+l +Dex
Fig. 3. Indomethacin reverses dexmedetomidine-induced inhibition of
cAMP-stimulated Pf. Each line represents a single experiment. Mean SE
is shown above each experimental period. Each period was significantly
different from the previous period (P < 0.001). Abbreviations are: cAMP,
8-chlorophenylthio cAMP (0.1 mM); Dex, dexmedetomidine (100 nM); I,
indomethacin [0.1 mvi (A), 5 jLM (B)I.
detomidine then reduced Pf, which increased upon removal of
dexmedetomidine.
Effect of dexmedetomidine added after the addition of
staurosporine
Staurosporine raised AVP-stimulated P1 but this increase was
not statistically significant (Fig. 7). The addition of 100 mel
dexmedetomidine significantly reduced P and the subsequent
addition of 100 nM atipamezole reversed the inhibition.
Effect of dexmedetomidine added in the presence of both
indomethacin and staurosporine
To determine if the combination of indomethacin and stauro-
sporine would induce an additive effect on P1, 10 nM staurosporine
was applied after S M indomethacin had already increased
AVP-stimulated Pf (Fig. 8). Staurosporine did not change P
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Fig. 4. Staurosporine reverses dexmedetomidine-induced inhibition of
AVP.stimulated P1 (A) and cAMP-stimulated P1 (B). Each line represents
a single experiment. Mean SE is shown above each experimental period.
In A, AVP+Dex period was different from AVP period (P < 0.001),
AVP+Dex+St was different from AVP+Dex (P < 0.05), and AVP+Dex
was different from AVP+Dex+St (P < 0.01). In B, cAMP+Dex was
different from cAMP (P < 0.005), and cAMP+Dex was different from
cAMP+Dex+St (P < 0.05). Abbreviations are: AVP, arginine vasopressin
(220 pM); cAMP, 8-chlorophenylthio cAMP (0.1 mM); Dcx, dexmedeto-
midine (100 nM); St, staurosporine (10 nM).
Fig. 5. Dexmedetomidine inhibits AVP.stimulated Pf when added after
the addition of indomethacin. Each line represents a single experiment.
Mean SE is shown above each experimental period. AVP+I period was
significantly different from AVP period (P < 0.005). Each other period
was significantly different from the previous period (P < 0.001). Abbre-
viations are: AVP, arginine vasopressin (220 pM); Dcx, dexmedetomidine
(100 nM); I, indomethacin [0.1 mtvt (A), 5 tLM (B)].
5 .LM significantly increased Pf from control values and this was
maintained through four experimental periods (that is, 200 to 220
mi. P returned to control values upon removal of indometha-
Experiments shown in Figure lOB were conducted to determine
if indomethacin would increase AVP-stimulated Pf after long-
term exposure to AVP. The AVP-stimulated Pf remained stable
through four experimental periods, and 5 jIM indomethacin
significantly increased Pf in the final period.
DISCUSSION
It is well-established that a2 adrenoceptors inhibit transport in
the mammalian collecting duct [1—4, 18]. Krothapalli et al [18]
reported that 1 jIM phenylephrine reduced AVP-stimulated P in
the rabbit CCD and Krothapalli and Suki [3] showed that this
effect is a2-mediated, since the a2 antagonist yohimbine reversed
the effect but the a1 antagonist prazosin did not. They also
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under this condition. The subsequent addition of 100 nM dexme-
detomidine significantly reduced Pf.
Effect of staurosporine alone on P1
Staurosporine at 10 n significantly and reversibly increased
AVP-stimulated P (Fig. 9A). In Figure 9B, staurosporine signif-
icantly increased basal Pf whereupon the subsequent addition of
AVP markedly elevated the staurosporine-induced increase. Pf
decreased upon the removal of staurosporine in the final period.
Effect of indomethacin alone on P1
Experiments shown in Figure 1OA were conducted to determine
if indomethacin would elevate basal Pf (Fig. 10). Indomethacin at
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Fig. 6. Dexmedetomidine inhibits cAMP-stimulated P. when added after
the addition of indomethacin. Each line represents a single experiment.
Mean st is shown above each experimental period. cAMP+I period was
different from cAMP period (P < 0.01). Each other period was signifi-
cantly different from the previous period (P < 0.001). Abbreviations are:
cAMP, 8-chlorophenylthio cAMP (0.1 mM); Dcx, dcxmedetomidine (100
nM); I, indomethacin (5 sM).
Control AVP AVP AVP + AVP +
+st st+
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Fig. 7. Dexmedetomidine inhibits Pf when added after the addition of
staurosporine. Each line represents a single experiment. Mean SE is
shown above each experimental period. AVP+St period was not different
from the AVP period. Each other period was significantly different from
the previous period (P < 0.001). Abbreviations are: AVP, arginine
vasopressin (220 pM); Dcx, dexmedetomidine (100 nM); St, staurosporine
(10 nM); Ati, atipamezole (100 nM).
demonstrated that 1 J.LM clonidinc, an a2 agonist, reduced AVP-
stimulated P1, but clonidine failed to reduce P1 stimulated by 8
bromoadenosine cAMP. This indicated that a2 adrenoceptors
inhibit AVP-stimulated P1 in the rabbit CCD via pre-cAMP events
caused likely by the inhibition of adenylyl cyclase.
In the mammalian nephron, a2 adrenoceptors are coupled to a
G protein that inhibits adenylyl cyclase [7, 8, 19—25]. Umemura et
al [81 reported that epinephrine reduced AVP-stimulated cAMP
accumulation in the rat CCD, and yohimbine prevented the
inhibition but prazosin did not. Edwards and Gellai [20] reported
that the a2 agonist B-HT 933 inhibited AVP-stimulated Pf in the
rat papillary collecting duet and pertussis toxin attenuated this
effect. In a later study Gellai and Edwards [6] reported that B-HT
933 inhibited AVP-stimulated cAMP accumulation in outer mcd-
ullary collecting ducts. Charbardés et al [5] demonstrated that 1
LM clonidine inhibited AVP-stimulated cAMP accumulation in
the rat CCD. As well, Maeda et al [7] reported that I /LM elonidine
reduced AVP-stimulated cAMP accumulation in the rat IMCD.
Thus, evidence accumulated over the past several years clearly
indicates that a2 adrenoceptors in the mammalian collecting duct
inhibit transport and they are negatively coupled to adenylyl
cyclase. Based on these findings and the well-documented evi-
dence that AVP increases salt and water transport in the collect-
ing duct via stimulating adenylyl cyclase, it is logical to conclude
that the mechanism of a2-mediated transport inhibition occurs via
reduction in cellular cAMP levels. However, recent evidence
suggests that this mechanism is more complicated.
Hawk et al [2] reported that epinephrine completely reduced
AVP-stimulated Pf, lh, and transepithelial voltage (Vt) in the rat
CCD. Interestingly, epinephrine significantly reduced these trans-
port properties when stimulated by 8-bromoadenosine cAMP.
Yohimbine reversed the epinephrine-induced inhibition whereas
the a1 antagonist coryanthine did not, confirming an a2-mediated
event. Recently, we reported that dexmedetomidine completely
inhibited both AVP- and dibutyryl cAMP-stimulated Pf in the rat
IMCD [4] and partially inhibited 8CPTcAMP-stimulated Pf in the
rat CCD [261. These data showing that a2-mediated inhibition of
transport in the CCD and IMCD occurs in the presence of
constant levels of cAMP indicate the involvement of unknown
cellular mediators.
Considerable evidence indicates that prostaglandins and PKC
activation reduce transport in the collecting duct [5, 9—11, 27—311.
The key findings that led us to hypothesize that prostaglandins
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Fig. 8. Dexmedetomidine inhibits AVP.stimulated Pf after the addition
of indomethacin and staurosporine. Each line represents a single exper-
iment. Mean SE is shown above each experimental period. AVP+I+St
period was not different from AVP + I period (that is, staurosporine did
not produce an additive effect). Each other period was significantly
different from the previous period (P < 0.001). Abbreviations are: AVP,
arginine vasopressin (220 pM); Dcx, dexmedetomidine (100 nM); I,
indomethacin (0.1 mM); St, staurosporine (10 nM); Ati, atipamezole (100
nM).
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Control St St + AVP AVP
Fig. 9. Staurosporine increases AVP-stimulated and basal P1. Each line
represents a single experiment. Mean SE is shown above each experi-
mental period. mA, AVP+St period was different from AVP (P < 0.01).
In B, each period was significantly different from the previous period (P <
0.001). Abbreviations are: AVP, arginine vasopressin (220 pM); St, stau-
rosporine (10 nM).
and/or PKC are involved in the a2-mediated inhibitory mecha-
nism came from Nadler, Zimpelmann and Hébert [91, who
reported that prostaglandin E2 (PGE2) reversibly inhibited AVP-
and 8CPTcAMP-stimulated P in the isolated rat IMCD. In
addition, 10 nM staurosporinc prevented the PGE2-mediated
inhibition of 8CPTcAMP-stimulated P0 The authors suggested
that PKC, activated by prostaglandins, played an important role in
regulating water permeability in the IMCD.
Since PKC and prostaglandins inhibit transport in the IMCD
via post-cAMP cellular events and a2-mediated inhibition occurs
in the presence of constant cAMP levels, we decided to test the
possibility that a2 agonists utilize these mediators to inhibit P1 in
the IMCD. Indomethacin, a prostaglandin synthesis inhibitor,
reversed dexmedetomidine-induced inhibition of AVP-stimulated
Pf (Fig. 1) and 8CPTcAMP-stimulated Pf (Fig. 3). We used
indomethacin at two concentrations: 0.1 m and 5 jIM. The higher
concentration yielded a higher reversal in both sets of experiments
although the indomethacin-induced reversal was statistically sig-
nificant in all studies. It is likely that at the higher concentration,
AVP AVP+
I ndo
Fig. 10. Indomethacin increases AVP-stimulated and basal P1. Each line
represents a single experiment. Mean SE is shown above each experi-
mental period. (A) Indomethacin at 5 JIM increased basal P1 and this was
maintained through four experimental periods (—200 to 220 mm). Re-
moval of indomethacin reduced Pf back to control levels. The control
periods were different from the indomethacin periods (P < 0.001). (B)
Indomethacin at 5 JIM increased AVP-stimulated Pf. Indomethacin was
added after four complete experimental periods with AVP (—200 to 220
mm). The AVP+Indo was different from the AVP periods (P < 0.001).
intracellular events occurred in addition to the inhibition of
prostaglandin synthesis.
To test the possible involvement of PKC, we used the PKC-
inhibitor staurosporine at 10 nM, which was the concentration that
prevented the PGE2-induced inhibition of 8CPTcAMP-stimu-
lated P in the IMCD [9]. Staurosporine reversed the dexmedeto-
midine-induced inhibition of AVP-stimulated P (Fig. 4A) and the
same trend was observed with 8CPTcAMP-stimulated P1, al-
though that reversal was not statistically significant (Fig. 4B).
These findings suggest that prostaglandins and PKC are involved
in a2-mediated inhibition of Pr..
However, interpretation of these results is complicated from
the observations that dexmedetomidine inhibited Pf in the pres-
ence of indomethacin (Figs. 5 and 6), staurosporine (Fig. 7), or
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both (Fig. 8) when dexmedetomidine was added after these
agents. Although an explanation for this interesting dichotomy
cannot be made at this time, it may be helpful to recognize that a2
agonists activate multiple signal transduction pathways.
MacNulty et at [32] reported that the a2-C10 (an a2 clone that
maps to chromosome 10) adrenoceptor from human platelets
expressed in rat fibroblasts demonstrated regulation of adenylyl
cyclase and phospholipase D activity, indicating that a2 adreno-
ceptors can regulate distinct effector systems. Fraser et at [33]
expressed the human a2 adrenoceptor in Chinese hamster ovary
cells. The expressed receptor demonstrated simultaneous regula-
tion of a pertussis toxin-sensitive mechanism leading to forskolin-
induced attenuation of adenylyl cyclase activity and a pertussis
toxin-insensitive pathway, leading to the potentiation of forskolin-
activated cAMP levels. Cotecchia et al [34] expressed the DNAs
encoding a2 receptors in hamster lung fibroblasts and reported
that a2 adrenergic activation simultaneously inhibited adenylyl
cyclase and stimulated phosphoinositide hydrolysis.
It is particularly interesting to recognize the signal transduction
pathway in platelets proposed by Sweatt et al [35], who studied the
effects of epinephrine on human platelet secretion. They pro-
posed a model where the adrenergic agonist mobilizes a small
pooi of arachidonic acid that stimulate cyclooxygenase products,
which then lead to activation of phospholipase C. Indomethacin
prevented the epinephrine-induced stimulation of inositol phos-
phate, suggesting that epinephrine stimulated phospholipase C
indirectly via the mobilization of arachidonic acid.
The findings described in the preceding two paragraphs indicate
that a2 adrenoceptors activate more than just the G1-mediated
inhibition of adenylyl cyclase. Whether or not this has relevance
with respect our results is for now only speculative. It is important
to recognize that the physiological relationship between prosta-
glandins and phospholipase C producing a biological response has
been observed in different cell types, (that is, Nadler et al [9] and
Sweatt et a! [35]), and our results suggest that a2 adrenoceptors
utilize this relationship. When staurosporine was added to the
indomethacin-induced increase in AVP-stimulated P0 no change
in Pf was measured (Fig. 8). This is consistent with the above
studies in that it suggests that the staurosporine-induced increase
in Pf is dependent upon an indomethacin-sensitive agent.
Results shown in Figure 9 demonstrate that staurosporine
elevated not only AVP-stimulated Pf (Fig. 9A), but also basal Pf
(Fig. 9B). In addition, indomethacin elevated basal Pf and this was
maintained through four experimental periods (200 to 220 mm)
(Fig. bA), and indornethacin elevated AVP-stimulated Pf after
four experimental periods in the presence of AVP (Fig. lOB).
These findings suggest that indomethacin and staurosporine-
sensitive mediators play important roles in regulating overall
water permeability in the IMCD.
The purpose of this study was to determine if a2 mediated
inhibition of Pf in the IMCD involved prostagland ins or PKC. The
major findings are: (1) indomethacin reversed dexmedetomidine-
induced inhibition of AVP- and 8CPTcAMP-stimulated Pf; (2)
staurosporine reversed the dexmedetomidine-induced inhibition
of AVP-stimulated P1 and appeared to do the same with 8CPT-
cAMP-stimulated P1, although these results were not as definite;
(3) dexmedetomidine inhibited the indomethacin-induced in-
crease in AVP- and 8CPTcAMP-stimulated P1; (4) dexmedetomi-
dine inhibited the staurosporine-induced increase in AVP-stimu-
lated Pf; and (5) dexmedetomidine inhibited Pf in the presence of
both indomethacin and staurosporine. Additional results indicate
that indomethacin- and staurosporine-sensitive mediators play
roles in modulating basal water permeability.
The a2-mediated inhibitory mechanism of water permeability in
the rat IMCD is more involved than the mere inhibition of
adenylyl cyclase, and other second messengers indeed participate.
It will be important to focus on the specific a2 adrenoceptor
subtypes and the associated mechanisms of action in the collecting
duct in order to develop possible therapeutic agents designed to
influence these mechanisms.
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APPENDIX
Abbreviations used in this article are: PKC, protein kinase C; cAMP,
3-5' cyclic adenosine monophosphate; 8CPTcAMP, 8-chlorophenylthio
cAMP; Dex, dexmedetoniidine; I, indomethacin; IMCD, inner medullary
collecting duct; AVP, arginine vasopressin; P1, osmotic water permeability;
Ih, lumen-to-bath sodium transport; J, net fluid flux; G1, inhibitory G
protein; CCD, cortical collecting duct; PGE2, prostaglandin E2; V,
perfusion rate; V0, collection rate; Ink, inulin activities in the perfusate;
In0, inulin activities in the collected fluid; V,, transepithelial voltage.
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